Welcome to our dedicated page for Scribe Therapeutics SEC filings (Ticker: SCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scribe Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scribe Therapeutics's regulatory disclosures and financial reporting.
Scribe Therapeutics Inc. reported that its Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws became effective on July 27, 2026 in connection with the closing of its initial public offering of common stock.
The board of directors and stockholders had previously approved these governance documents to become effective immediately prior to the offering’s closing. Key terms of the charter and bylaws are described in the “Description of Capital Stock” section of the final prospectus dated July 23, 2026, and the full documents are filed as Exhibits 3.1 and 3.2.
Scribe Therapeutics Inc. is conducting an initial public offering of 8,580,000 shares of common stock at $15.00 per share, for a gross offering size of $128.7 million. Net proceeds to the company are expected to be $13.95 per share, or $119.7 million before expenses, with underwriters holding a 30‑day option to purchase up to 1,287,000 additional shares. A concurrent private placement will sell 500,000 shares to Sanofi at the IPO price; this placement is contingent on but not a condition to the IPO.
The company is a clinical-stage biotechnology firm developing in vivo CRISPR-based genetic medicines, led by STX‑1150 for durable LDL‑C lowering in a first‑in‑human trial in up to 64 adults, with initial data expected in the first half of 2027, and preclinical programs STX‑1200 and STX‑1400 targeting Lp(a) and APOC3. Operations have been funded primarily through equity, collaborations, and grants; Scribe reported $51.2 million in 2025 collaboration revenue and a $21.8 million net loss, with an accumulated deficit of $175.1 million and $49.7 million in cash, cash equivalents, and short‑term investments as of March 31 2026.
Audited financial statements include a going‑concern warning, as existing cash would not support operations for twelve months absent new capital. Management believes current cash plus IPO and private‑placement proceeds will fund operations into the first half of 2029, but the business remains highly dependent on successful development of its pipeline and future financings. Scribe is an emerging growth company and smaller reporting company and will provide reduced disclosures under applicable regulations.
Scribe Therapeutics, Inc. insider Brett Staahl, reported as a ten percent owner, filed an initial statement of beneficial ownership. He holds 524,336 shares of Common Stock directly. In addition, he reports four stock option awards over Common Stock with exercise prices of $3.08, $6.40 and $19.13, covering 2,462, 17,798, 4,755 and 1,688 underlying shares, expiring between 2030 and 2036. Certain options are fully vested, while one grant began vesting 25% on January 1, 2026 with the remainder vesting in equal monthly installments subject to continued service.